248 research outputs found
Environmental behavior of 14C-tagged polyacrylate polymer: Flow tank studies of retention in sand
A highly absorbent consumer-product, polyacrylate polymer material tagged with 14C was dosed to a simulated diaper and buried in a horizontal flow tank containing sand. Two slightly different formulations of the polymer exhibited a mobile fraction, 1.9 percent and 3.48 percent of which was discharged in the tank effluent during the passage of 6 pore volumes. Most of the remainder was retarded along the flow path near the source by the sand. It is expected that more conventional landfill soils would provide even greater retention of the polymer materials studied. The use of a 14C-tagged polymer proved to be a successful method for studying the behavior of these complex materials; pilot-scale studies are planned in lysimeters to determine if microbial decomposition affects the migration of these polymers under landfill conditions.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/26930/1/0000496.pd
Mixed configuration-interaction and many-body perturbation theory calculations of energies and oscillator strengths of J=1 odd states of neon
Ab-initio theory is developed for energies of J=1 particle-hole states of
neutral neon and for oscillator strengths of transitions from such states to
the J=0 ground state. Hole energies of low-Z neonlike ions are evaluated.Comment: 5 pages, 1 figure, 4 table
10-Year Resource Utilization and Costs for Cardiovascular Care
Background: Cardiovascular disease (CVD) imparts a heavy economic burden on the U.S. health care system. Evidence regarding the long-term costs after comprehensive CVD screening is limited. Objectives: This study calculated 10-year health care costs for 6,814 asymptomatic participants enrolled in MESA (Multi-Ethnic Study of Atherosclerosis), a registry sponsored by the National Heart, Lung, and Blood Institute, National Institutes of Health. Methods: Cumulative 10-year costs for CVD medications, office visits, diagnostic procedures, coronary revascularization, and hospitalizations were calculated from detailed follow-up data. Costs were derived by using Medicare nationwide and zip codeâspecific costs, inflation corrected, discounted at 3% per year, and presented in 2014 U.S. dollars. Results: Risk factor prevalence increased dramatically and, by 10 years, diabetes, hypertension, and dyslipidemia was reported in 19%, 57%, and 53%, respectively. Self-reported symptoms (i.e., chest pain or shortness of breath) were common (approximately 40% of enrollees). At 10 years, approximately one-third of enrollees reported having an echocardiogram or exercise test, whereas 7% underwent invasive coronary angiography. These utilization patterns resulted in 10-year health care costs of 2 of every 7,700 for low-risk (Framingham risk score \u3c6%, 0 CACS, and normal glucose measurements at baseline) to \u3e74 million of the $155 million consumed by MESA participants. Conclusions: Longitudinal patterns of health care resource use after screening revealed new evidence on the economic burden of treatment and testing patterns not previously reported. Maintenance of a healthy population has the potential to markedly reduce the economic burden of CVD among asymptomatic individuals
The Holographic Supercurrent Anomaly
The \gamma-trace anomaly of supersymmetry current in a supersymmetric gauge
theory shares a superconformal anomaly multiplet with the chiral R-symmetry
anomaly and the Weyl anomaly, and its holographic reproduction is a valuable
test to the AdS/CFT correspondence conjecture. We investigate how the
\gamma-trace anomaly of the supersymmetry current of {\cal N}=1
four-dimensional supersymmetric gauge theory in an {\cal N}=1 conformal
supergravity background can be extracted out from the gauged
supergravity in five dimensions. It is shown that the reproduction of this
super-Weyl anomaly originates from the following two facts: First the {\cal
N}=2 bulk supersymmetry transformation converts into {\cal N}=1 superconformal
transformation on the boundary, which consists of {\cal N}=1 supersymmetry
transformation and special conformal supersymmetry (or super-Weyl)
transformation; second the supersymmetry variation of the bulk action of
five-dimensional gauged supergravity is a total derivative. The
non-compatibility of supersymmetry and the super-Weyl transformation invariance
yields the holographic supersymmetry current anomaly. Furthermore, we speculate
on that the contribution from the external gauge and gravitational background
fields to the superconformal anomaly may have different holographic origin.Comment: 22 pages, RevTex; more correction
Multiwavelength studies of MHD waves in the solar chromosphere: An overview of recent results
The chromosphere is a thin layer of the solar atmosphere that bridges the
relatively cool photosphere and the intensely heated transition region and
corona. Compressible and incompressible waves propagating through the
chromosphere can supply significant amounts of energy to the interface region
and corona. In recent years an abundance of high-resolution observations from
state-of-the-art facilities have provided new and exciting ways of
disentangling the characteristics of oscillatory phenomena propagating through
the dynamic chromosphere. Coupled with rapid advancements in
magnetohydrodynamic wave theory, we are now in an ideal position to thoroughly
investigate the role waves play in supplying energy to sustain chromospheric
and coronal heating. Here, we review the recent progress made in
characterising, categorising and interpreting oscillations manifesting in the
solar chromosphere, with an impetus placed on their intrinsic energetics.Comment: 48 pages, 25 figures, accepted into Space Science Review
Size Doesn't Matter: Towards a More Inclusive Philosophy of Biology
notes: As the primary author, OâMalley drafted the paper, and gathered and analysed data (scientific papers and talks). Conceptual analysis was conducted by both authors.publication-status: Publishedtypes: ArticlePhilosophers of biology, along with everyone else, generally perceive life to fall into two broad categories, the microbes and macrobes, and then pay most of their attention to the latter. âMacrobeâ is the word we propose for larger life forms, and we use it as part of an argument for microbial equality. We suggest that taking more notice of microbes â the dominant life form on the planet, both now and throughout evolutionary history â will transform some of the philosophy of biologyâs standard ideas on ontology, evolution, taxonomy and biodiversity. We set out a number of recent developments in microbiology â including biofilm formation, chemotaxis, quorum sensing and gene transfer â that highlight microbial capacities for cooperation and communication and break down conventional thinking that microbes are solely or primarily single-celled organisms. These insights also bring new perspectives to the levels of selection debate, as well as to discussions of the evolution and nature of multicellularity, and to neo-Darwinian understandings of evolutionary mechanisms. We show how these revisions lead to further complications for microbial classification and the philosophies of systematics and biodiversity. Incorporating microbial insights into the philosophy of biology will challenge many of its assumptions, but also give greater scope and depth to its investigations
Functional and quality of life outcomes of localised prostate cancer treatments (prostate testing for cancer and treatment [ProtecT] study)
Objective
To investigate the functional and quality of life (QoL) outcomes of treatments for localised prostate cancer and inform treatment decision-making.
Patients and Methods
Men aged 50â69âyears diagnosed with localised prostate cancer by prostate-specific antigen testing and biopsies at nine UK centres in the Prostate Testing for Cancer and Treatment (ProtecT) trial were randomised to, or chose one of, three treatments. Of 2565 participants, 1135 men received active monitoring (AM), 750 a radical prostatectomy (RP), 603 external-beam radiotherapy (EBRT) with concurrent androgen-deprivation therapy (ADT) and 77 low-dose-rate brachytherapy (BT, not a randomised treatment). Patient-reported outcome measures (PROMs) completed annually for 6âyears were analysed by initial treatment and censored for subsequent treatments. Mixed effects models were adjusted for baseline characteristics using propensity scores.
Results
Treatment-received analyses revealed different impacts of treatments over 6âyears. Men remaining on AM experienced gradual declines in sexual and urinary function with age (e.g., increases in erectile dysfunction from 35% of men at baseline to 53% at 6âyears and nocturia similarly from 20% to 38%). Radical treatment impacts were immediate and continued over 6âyears. After RP, 95% of men reported erectile dysfunction persisting for 85% at 6âyears, and after EBRT this was reported by 69% and 74%, respectively (Pâ<â0.001 compared with AM). After RP, 36% of men reported urinary leakage requiring at least 1âpad/day, persisting for 20% at 6âyears, compared with no change in men receiving EBRT or AM (Pâ<â0.001). Worse bowel function and bother (e.g., bloody stools 6% at 6âyears and faecal incontinence 10%) was experienced by men after EBRT than after RP or AM (Pâ<â0.001) with lesser effects after BT. No treatment affected mental or physical QoL.
Conclusion
Treatment decision-making for localised prostate cancer can be informed by these 6-year functional and QoL outcomes
Implicating genes, pleiotropy, and sexual dimorphism at blood lipid loci through multi-ancestry meta-analysis
Funding Information: GMP, PN, and CW are supported by NHLBI R01HL127564. GMP and PN are supported by R01HL142711. AG acknowledge support from the Wellcome Trust (201543/B/16/Z), European Union Seventh Framework Programme FP7/2007â2013 under grant agreement no. HEALTH-F2-2013â601456 (CVGenes@Target) & the TriPartite Immunometabolism Consortium [TrIC]-Novo Nordisk Foundationâs Grant number NNF15CC0018486. JMM is supported by American Diabetes Association Innovative and Clinical Translational Award 1â19-ICTS-068. SR was supported by the Academy of Finland Center of Excellence in Complex Disease Genetics (Grant No 312062), the Finnish Foundation for Cardiovascular Research, the Sigrid Juselius Foundation, and University of Helsinki HiLIFE Fellow and Grand Challenge grants. EW was supported by the Finnish innovation fund Sitra (EW) and Finska LĂ€karesĂ€llskapet. CNS was supported by American Heart Association Postdoctoral Fellowships 15POST24470131 and 17POST33650016. Charles N Rotimi is supported by Z01HG200362. Zhe Wang, Michael H Preuss, and Ruth JF Loos are supported by R01HL142302. NJT is a Wellcome Trust Investigator (202802/Z/16/Z), is the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT 217065/Z/19/Z), is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-1215â2001) and the MRC Integrative Epidemiology Unit (MC_UU_00011), and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A19169). Ruth E Mitchell is a member of the MRC Integrative Epidemiology Unit at the University of Bristol funded by the MRC (MC_UU_00011/1). Simon Haworth is supported by the UK National Institute for Health Research Academic Clinical Fellowship. Paul S. de Vries was supported by American Heart Association grant number 18CDA34110116. Julia Ramierz acknowledges support by the People Programme of the European Unionâs Seventh Framework Programme grant n° 608765 and Marie Sklodowska-Curie grant n° 786833. Maria Sabater-Lleal is supported by a Miguel Servet contract from the ISCIII Spanish Health Institute (CP17/00142) and co-financed by the European Social Fund. Jian Yang is funded by the Westlake Education Foundation. Olga Giannakopoulou has received funding from the British Heart Foundation (BHF) (FS/14/66/3129). CHARGE Consortium cohorts were supported by R01HL105756. Study-specific acknowledgements are available in the Additional file : Supplementary Note. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services. Publisher Copyright: © 2022, The Author(s).Background: Genetic variants within nearly 1000 loci are known to contribute to modulation of blood lipid levels. However, the biological pathways underlying these associations are frequently unknown, limiting understanding of these findings and hindering downstream translational efforts such as drug target discovery. Results: To expand our understanding of the underlying biological pathways and mechanisms controlling blood lipid levels, we leverage a large multi-ancestry meta-analysis (N = 1,654,960) of blood lipids to prioritize putative causal genes for 2286 lipid associations using six gene prediction approaches. Using phenome-wide association (PheWAS) scans, we identify relationships of genetically predicted lipid levels to other diseases and conditions. We confirm known pleiotropic associations with cardiovascular phenotypes and determine novel associations, notably with cholelithiasis risk. We perform sex-stratified GWAS meta-analysis of lipid levels and show that 3â5% of autosomal lipid-associated loci demonstrate sex-biased effects. Finally, we report 21 novel lipid loci identified on the X chromosome. Many of the sex-biased autosomal and X chromosome lipid loci show pleiotropic associations with sex hormones, emphasizing the role of hormone regulation in lipid metabolism. Conclusions: Taken together, our findings provide insights into the biological mechanisms through which associated variants lead to altered lipid levels and potentially cardiovascular disease risk.Peer reviewe
Search for heavy resonances decaying into a Z or W boson and a Higgs boson in final states with leptons and b-jets in 139 fbâ1 of pp collisions at sâ = 13 TeV with the ATLAS detector
This article presents a search for new resonances decaying into a Z or W boson and a 125 GeV Higgs boson h, and it targets the ÎœÎœÂŻÂŻÂŻbbÂŻÂŻ, â+ââbbÂŻÂŻ, or â±ΜbbÂŻÂŻ final states, where â = e or ÎŒ, in proton-proton collisions at sâ = 13 TeV. The data used correspond to a total integrated luminosity of 139 fbâ1 collected by the ATLAS detector during Run 2 of the LHC at CERN. The search is conducted by examining the reconstructed invariant or transverse mass distributions of Zh or Wh candidates for evidence of a localised excess in the mass range from 220 GeV to 5 TeV. No significant excess is observed and 95% confidence-level upper limits between 1.3 pb and 0.3 fb are placed on the production cross section times branching fraction of neutral and charged spin-1 resonances and CP-odd scalar bosons. These limits are converted into constraints on the parameter space of the Heavy Vector Triplet model and the two-Higgs-doublet model
Search for light long-lived neutral particles that decay to collimated pairs of leptons or light hadrons in pp collisions at sâ = 13 TeV with the ATLAS detector
A search for light long-lived neutral particles with masses in the O(MeVâGeV) range is presented. The analysis targets the production of long-lived dark photons in the decay of a Higgs boson produced via gluonâgluon fusion or in association with a W boson. Events that contain displaced collimated Standard Model fermions reconstructed in the calorimeter or muon spectrometer are selected in 139 fbâ1 of sâ = 13 TeV pp collision data collected by the ATLAS detector at the LHC. Background estimates for contributions from Standard Model processes and instrumental effects are extracted from data. The observed event yields are consistent with the expected background. Exclusion limits are reported on the production cross-section times branching fraction as a function of the mean proper decay length cÏ of the dark photon, or as a function of the dark-photon mass and kinetic mixing parameter that quantifies the coupling between the Standard Model and potential hidden (dark) sectors. A Higgs boson branching fraction above 1% is excluded at 95% CL for a Higgs boson decaying into two dark photons for dark-photon mean proper decay lengths between 10 mm and 250 mm and dark photons with masses between 0.4 GeV and 2 GeV
- âŠ